Le Lézard
Classified in: Ebola virus, Health, Business
Subject: ERN

Essity: Year-end Report 2023


STOCKHOLM, Jan. 25, 2024 /PRNewswire/ --

JANUARY 1 ? DECEMBER 31, 2023
(compared with the corresponding period a year ago)

CEO'S COMMENTS

Highest profit ever and strong platform for growth

Essity reached a net sale in 2023 of SEK 147bn and adjusted EBITA of SEK 18.9bn, excluding Vinda. Having offset cost inflation through price increases and improved the structural profitability, we increased focus during the fourth quarter on volume growth and market shares. The company Isola Castle Ltd has announced that it will make a pre-conditional public offer for the shares in Vinda, entailing a shift for Essity toward a product portfolio with a higher margin and lower volatility. 

Structurally improved profitability

We can look back at a year with high sales growth and a significantly higher EBITA margin, where all business areas made positive contributions through profitable growth and margin improvements. Measures aimed at structurally improving profitability have had an effect. In Health & Medical, decisive price increases have led to a sharp increase in the margin. For Professional Hygiene, restructuring measures in North America and Europe increased the structural margin by approximately 2 percentage points. In Consumer Goods, the strong volume growth for Incontinence Products Retail and Feminine Care continued. Moreover, in 2023 we successfully reversed the trend for Baby Care, which is now demonstrating a strong improvement. For Consumer Tissue, price increases have yielded higher and more stable margins.

The adjusted return on capital employed improved in 2023 by 5.5 percentage points to 16.4%. Adjusted earnings per share were SEK 17.56, an increase of 51%. For the 2023 fiscal year, the Board of Directors proposes an increase in the dividend of 7% to SEK 7.75 per share.

Strong fourth quarter
For the fourth quarter, sales growth, including organic sales growth and acquisitions, was -0.7%. Volumes were lower, mainly due to the focus on profitable growth and decisions earlier in the year to carry out restructuring measures and exit contracts with insufficient profitability. These decisions have long-term improved Essity's structural margin and, excluding these measures, volumes increased by 1.2%. Adjusted EBITA increased 18% and the margin by 2.1 percentage points to 13.3%. Our efforts to increase productivity and achieve a more efficient use of resources have led to savings in cost of goods sold of SEK 377m in the fourth quarter. Meanwhile, we have invested for future volume growth and higher market shares by intensifying sales and marketing activities. We have launched innovations in all business areas that improved customer and consumer offerings and increased our market shares during the quarter.

Portfolio shift
We have continued to grow in the categories and sales channels with the highest market growth and returns. The earlier acquisitions of, for example, Knix, Hydrofera and Legacy, have strengthened our offerings and contributed with high growth.

We have undertaken to accept the offer from Isola Castle Ltd in respect of all shares in Vinda. It represents a very attractive offer for Essity and our shareholders, and also provides a product portfolio with higher and more stable returns. Consumer Tissue's share of net sales in 2023 will decrease from 41% to 33%.

An even more sustainable Essity
By providing hygiene and health solutions to a billion people every day across the globe, Essity has a substantial opportunity to influence people and the environment. We have taken further steps toward net zero emissions of greenhouse gas emissions by 2050 and for Science Based Targets, Scope 1 and 2, the decrease is -26% for the 2016-2023 period. Essity has been named one of the world's most sustainable companies by Corporate Knights by its inclusion in the Global 100 list representing the top 1% of companies in the world in terms of sustainability performance. For the third consecutive year, we were designated a Diversity Leader by the Financial Times and were included in the S&P Global Sustainability Yearbook for the second consecutive year.

Focus on profitable growth in 2024
Following many measures in 2023 and a structurally improved profitability, we have a strong platform for future growth.

Magnus Groth
President and CEO

FUTURE REPORTS
Essity's Annual Report for 2023 is intended to be published during the week starting February 26, 2024. In 2024, interim reports will be published on April 25, July 18 and October 24.

ANNUAL GENERAL MEETING
Essity's Annual General Meeting will be held in Stockholm, Sweden, on March 21, 2024.

INVITATION TO PRESENTATION OF THE YEAR-END REPORT FOR 2023
In conjunction with publication, a telephone and web presentation will be held at 09:00 CET, where President and CEO Magnus Groth will present and answer questions.

Presentation
Date: Thursday, January 25, 2024
Time: 09:00 CET
Link to web presentation: https://essity.videosync.fi/2024-01-25
Telephone: UK: +44 (0) 33 0551 02 00, USA: +1 786 697 35 01, SWE: +46 (0) 8 505 204 24. Please call in well in advance of the start of the presentation. Indicate: 'Essity'.
The presentation of the Year-end report will also be broadcast live on LinkedIn and X (Twitter)

Stockholm, January 25, 2024
Essity Aktiebolag (publ)

Magnus Groth
President and CEO 

For further information, please contact:

Fredrik Rystedt, CFO and Executive Vice President, +46 (0) 8 788 51 31
Sandra Ĺberg, Vice President Investor Relations, Group Function Finance, +46 (0) 70 564 96 89
Per Lorentz, Vice President Corporate Communications, Group Function Communications, +46 (0) 73 313 30 55

NB:

This interim report has not been reviewed by the company's auditors.

This information is such that Essity Aktiebolag (publ) is obligated to make public pursuant to the EU Market Abuse Regulation. This report has been prepared in both Swedish and English versions. In case of variations in the content between the two versions, the Swedish version shall govern. The information was submitted for publication, through the agency of Karl Stoltz, Media Relations Director, at 07:00 CET on January 25, 2024.

The following files are available for download:

https://mb.cision.com/Main/15798/3915146/2561965.pdf

The full report (PDF)

 


These press releases may also interest you

21 mar 2019
The "Europe Welding Equipment Market-Growth, Trends, and Forecast (2019 - 2024)" report has been added to ResearchAndMarkets.com's offering. Welding is one of the critical processes employed in the manufacturing...

21 mar 2019
Inovio Pharmaceuticals, Inc. announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses. This Phase 1 data was published in The Journal of Infectious Diseases and further supports the...

20 mar 2019
Merck , known as MSD outside the United States and Canada, and NGM Biopharmaceuticals, Inc. (NGM) today announced that Merck has exercised its option to extend the research phase of the companies' broad, strategic collaboration...

20 mar 2019
The shareholders in Sandvik Aktiebolag are convened to the Annual General Meeting to be held on Monday, 29 April 2019 at 3:00 p.m. at the Göransson Arena, Sätragatan 21, Sandviken, Sweden. RIGHT TO PARTICIPATE AND NOTICE Shareholders who wish to...

20 mar 2019
The Oslo Business for Peace Award is given to inspiring business leaders who have put society first. 2019's winners are: Dr Agbor Ashumanyi Ako, medical director of GiftedMom, Alice Laugher, CEO of Committed to...

19 mar 2019
The evolving competitive market has made it essential for the telecommunication industry to rethink traditional ways of doing business in terms of the impact on business models, service portfolios and technical architectures. Digital business support...



News published on and distributed by: